2014年9月19日（星期五）上午

Friday Morning, Sept.19^th, 2014

ESMO-CSCO Joint Symposium

Subject: The Treatment Progress in CRC

Venue: 1D Meeting Room, 1st Floor, Xiamen International Conference Center

Co-chairs:  Rui-Hua Xu (CSCO) 徐瑞华

           Jean-Yves Douillard (ESMO)

Keynote Speech

08:30~08:40  Introduction of ESMO Guidelines 

            Claus-Henning Köhne   Northwest German Cancer Center, Germany

08:40~08:45  Q&A

08:45~09:10  All RAS wt patients should be treated with EGFR inhibitors plus chemotherapy in first line

            Jean-Yves Douillard   ICO R. Gauducheau, France

09:10~09:15  Q&A

09:15~09:40  The role of VEGF inhibition in metastatic CRCs

            Claus-Henning Köhne   Northwest German Cancer Center, Germany

09:40~09:45  Q&A

09:45~10:05  The role of maintenance therapy in mCRC

            Rui-Hua Xu 徐瑞华   Sun Yat-Sen University Cancer Center, China

10:05~10:10  Q&A

10:10~10:30  Adjuvant chemotherapy for stage II Colon Cancer: Consensus and Controversy

            Gong Chen 陈  功   Sun Yat-Sen University Cancer Center, China

10:30~10:35  Q&A

10:35~10:55  "Head-to-head" or "Bench-to-bed": unmet demands of mCRC trials 

            Jun Zhang 张  俊   Shanghai Ruijin Hospital, China

10:55~11:00  Q&A

11:00~11:20  Targeted therapy for metastatic CRC 

            Jin Li 李  进   Fudan University Cancer Center, China

11:20~11:25  Q&A

Oral presentation 

11:25~11:35  Characteristics and prognostic significance of preoperative MRI assessed circumferential margin in Rectal Cancer

            Jun-Jie Peng 彭俊杰   Fudan University Cancer Center, China

11:35~11:45  Randomized controlled trial of intraportal chemotherapy combined with adjuvant chemotherapy (mFOLFOX6) for stage II and III colon cancer

            Wen-Ju Chang 常文举   Zhongshan Hospital, Fudan University, China

11:45~11:55  Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capeciatbine alone for locally advanced rectal cancer: a randomised, multicentre, phase 3 trial Clinical Trials number: NCT0071407

            Yan-Ru Feng 冯燕茹   Cancer Hospital and Institute, CAMS & PUMC, China

11:55~12:00  Abstract Discussion